Scottish stem cell companies Sistemic and Roslin Cells say they are working together with Scottish Development International to make the process of undertaking clinical trials in cell therapy easier, faster and more successful in reaching commercial realization.
The partnership will involve Health Sciences Scotland, NHS Research Scotland, NHS Scotland and leading technology-based industrial partners to offer cell therapy companies a streamlined process for clinical trials. This aims to provide access to the right patients, support product development, characterization and potency development, making the regulatory process much easier.
Investment in infrastructure
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze